Dyne Therapeutics, Inc.
DYN
$25.70
-$0.26-1.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 91.25M | 78.31M | 69.85M | 64.46M | 60.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 536.96M | 471.09M | 468.18M | 449.16M | 440.93M |
| Operating Income | -536.96M | -471.09M | -468.18M | -449.16M | -440.93M |
| Income Before Tax | -519.41M | -451.71M | -446.21M | -423.80M | -412.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -519.41 | -451.71 | -446.21 | -423.80 | -412.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -519.41M | -451.71M | -446.21M | -423.80M | -412.89M |
| EBIT | -536.96M | -471.09M | -468.18M | -449.16M | -440.93M |
| EBITDA | -534.80M | -468.99M | -466.14M | -447.19M | -439.04M |
| EPS Basic | -3.33 | -3.23 | -3.54 | -3.66 | -3.86 |
| Normalized Basic EPS | -2.08 | -2.02 | -2.21 | -2.29 | -2.41 |
| EPS Diluted | -3.33 | -3.23 | -3.54 | -3.66 | -3.86 |
| Normalized Diluted EPS | -2.08 | -2.02 | -2.21 | -2.29 | -2.41 |
| Average Basic Shares Outstanding | 619.92M | 568.34M | 513.21M | 467.58M | 426.65M |
| Average Diluted Shares Outstanding | 619.92M | 568.34M | 513.21M | 467.58M | 426.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |